Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in Advanced Ovarian Cancer
NCT00130520Phase 2Completed
- Sponsor
- University of Arizona
- Start
- Jun 2005
- Primary completion
- Jan 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by University of Arizona. Primary endpoints: Objective Response (Complete Partial, Stable and Progression) up to 4 years and Median Response Duration up to 96 weeks. Started Jun 2005; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00130520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130520.